TY - JOUR
T1 - Cryo-EM structures of human arachidonate 12S-lipoxygenase bound to endogenous and exogenous inhibitors
AU - Mobbs, Jesse I.
AU - Black, Katrina A.
AU - Tran, Michelle
AU - Burger, Wessel A.C.
AU - Venugopal, Hariprasad
AU - Holman, Theodore R.
AU - Holinstat, Michael
AU - Thal, David M.
AU - Glukhova, Alisa
N1 - Funding Information:
The authors acknowledge the use of facilities within the Monash Ramaciotti Cryo-EM platform and the Ian Holmes Imaging Centre at the Bio21 Molecular Science and Biotechnology Institute. The computational work was supported by the MASSIVE high-performance data processing facility (MASSIVE HPC) ( https://www.massive.org.au ).
Publisher Copyright:
© 2023 The American Society of Hematology
PY - 2023/10/5
Y1 - 2023/10/5
N2 - Human 12-lipoxygenase (12-LOX) is a key enzyme involved in platelet activation, and the regulation of its activity has been targeted for the treatment of heparin-induced thrombocytopenia. Despite the clinical importance of 12-LOX, the exact mechanisms by which it affects platelet activation are not fully understood, and the lack of structural information has limited drug discovery efforts. In this study, we used single-particle cryo-electron microscopy to determine high-resolution structures (1.7-2.8 Å) of human 12-LOX. Our results showed that 12-LOX can exist in multiple oligomeric states, from monomer to hexamer, which may affect its catalytic activity and membrane association. We also identified different conformations within the 12-LOX dimer, which likely represent different time points in its catalytic cycle. Furthermore, we identified small molecules bound to 12-LOX. The active site of the 12-LOX tetramer was occupied by an endogenous 12-LOX inhibitor, a long-chain acyl coenzyme A. In addition, we found that the 12-LOX hexamer can simultaneously bind to arachidonic acid and ML355, a selective 12-LOX inhibitor that has passed a phase 1 clinical trial for the treatment of heparin-induced thrombocytopenia and received a fast-track designation by the Food and Drug Administration. Overall, our findings provide novel insights into the assembly of 12-LOX oligomers, their catalytic mechanism, and small molecule binding, paving the way for further drug development targeting the 12-LOX enzyme.
AB - Human 12-lipoxygenase (12-LOX) is a key enzyme involved in platelet activation, and the regulation of its activity has been targeted for the treatment of heparin-induced thrombocytopenia. Despite the clinical importance of 12-LOX, the exact mechanisms by which it affects platelet activation are not fully understood, and the lack of structural information has limited drug discovery efforts. In this study, we used single-particle cryo-electron microscopy to determine high-resolution structures (1.7-2.8 Å) of human 12-LOX. Our results showed that 12-LOX can exist in multiple oligomeric states, from monomer to hexamer, which may affect its catalytic activity and membrane association. We also identified different conformations within the 12-LOX dimer, which likely represent different time points in its catalytic cycle. Furthermore, we identified small molecules bound to 12-LOX. The active site of the 12-LOX tetramer was occupied by an endogenous 12-LOX inhibitor, a long-chain acyl coenzyme A. In addition, we found that the 12-LOX hexamer can simultaneously bind to arachidonic acid and ML355, a selective 12-LOX inhibitor that has passed a phase 1 clinical trial for the treatment of heparin-induced thrombocytopenia and received a fast-track designation by the Food and Drug Administration. Overall, our findings provide novel insights into the assembly of 12-LOX oligomers, their catalytic mechanism, and small molecule binding, paving the way for further drug development targeting the 12-LOX enzyme.
UR - http://www.scopus.com/inward/record.url?scp=85169845030&partnerID=8YFLogxK
U2 - 10.1182/blood.2023020441
DO - 10.1182/blood.2023020441
M3 - Article
C2 - 37506345
AN - SCOPUS:85169845030
SN - 0006-4971
VL - 142
SP - 1233
EP - 1242
JO - Blood
JF - Blood
IS - 14
ER -